Novo Nordisk A/S (NVO)
NYSE: NVO · Real-Time Price · USD
45.68
-0.83 (-1.78%)
At close: Nov 7, 2025, 4:00 PM EST
45.87
+0.19 (0.42%)
After-hours: Nov 7, 2025, 7:59 PM EST
Novo Nordisk Employees
As of December 31, 2024, Novo Nordisk had 77,349 total employees, including 76,302 full-time and 1,047 part-time employees. The number of employees increased by 13,030 or 20.26% compared to the previous year.
Employees
77,349
Change (1Y)
13,030
Growth (1Y)
20.26%
Revenue / Employee
$640,996
Profits / Employee
$210,765
Market Cap
200.71B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 77,349 | 13,030 | 20.26% |
| Dec 31, 2023 | 64,319 | 9,134 | 16.55% |
| Dec 31, 2022 | 55,185 | 6,707 | 13.84% |
| Dec 31, 2021 | 48,478 | 3,155 | 6.96% |
| Dec 31, 2020 | 45,323 | 2,065 | 4.77% |
| Dec 31, 2019 | 43,258 | 56 | 0.13% |
| Dec 31, 2018 | 43,202 | 520 | 1.22% |
| Dec 31, 2017 | 42,682 | 711 | 1.69% |
| Dec 31, 2016 | 41,971 | 1,333 | 3.28% |
| Dec 31, 2015 | 40,638 | -319 | -0.78% |
| Dec 31, 2014 | 40,957 | 2,521 | 6.56% |
| Dec 31, 2013 | 38,436 | 3,705 | 10.67% |
| Dec 31, 2012 | 34,731 | 2,099 | 6.43% |
| Dec 31, 2011 | 32,632 | 2,149 | 7.05% |
| Dec 31, 2010 | 30,483 | 1,154 | 3.93% |
| Dec 31, 2009 | 29,329 | 2,754 | 10.36% |
| Dec 31, 2008 | 26,575 | 1,059 | 4.15% |
| Dec 31, 2007 | 25,516 | 1,903 | 8.06% |
| Dec 31, 2006 | 23,613 | 1,153 | 5.13% |
| Dec 31, 2005 | 22,460 | 1,735 | 8.37% |
| Dec 31, 2004 | 20,725 | 1,969 | 10.50% |
| Dec 31, 2003 | 18,756 | 751 | 4.17% |
| Dec 31, 2002 | 18,005 | 1,864 | 11.55% |
| Dec 31, 2001 | 16,141 | 2,389 | 17.37% |
| Dec 31, 2000 | 13,752 | 1,758 | 14.66% |
| Dec 31, 1999 | 11,994 | 345 | 2.96% |
| Dec 31, 1998 | 11,649 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
NVO News
- 10 hours ago - Millions more Americans could access obesity drugs after Trump's deals with Eli Lilly, Novo Nordisk - CNBC
- 14 hours ago - Eli Lilly, Novo Nordisk's Historic GLP-1 Pricing Deals - What Investors Need To Know - Seeking Alpha
- 22 hours ago - Fangzhou, Novo Nordisk Launch Initiative for AI-Powered Diabetes and Weight Management Solutions at CIIE - GlobeNewsWire
- 22 hours ago - Novo Nordisk shares fall after deal with Trump to slash obesity drug prices - Reuters
- 1 day ago - Here's how much weight loss drugs could cost you under Trump's deals with Eli Lilly, Novo Nordisk - CNBC
- 1 day ago - Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits - Reuters
- 1 day ago - Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® - PRNewsWire
- 1 day ago - Novo CEO says its bid for Metsera is higher - Reuters